Skip to main content

Table 1 Baseline characteristics and the efficacy outcomes of the plasma biomarker population compared to the overall study population

From: High baseline Tie1 level predicts poor survival in metastatic breast cancer

 Plasma biomarker population (n = 58)Overall study population (n = 65)
Age, years
 Median (range)58 (32–75)57 (32–75)
Menopausal status, n (%)
 Pre-menopausal9 (15.5)10 (15.4)
 Post-menopausal49 (84.5)55 (84.6)
History of early stage disease, n (%)52 (89.7)57 (87.7)
Disease free interval, n (%)
  ≤ 24 months10 (19.2)11 (19.3)
  > 24 months42 (80.8)46 (80.7)
Hormone receptor status, n (%)
 ER+ and/or PR+47 (81.0)53 (81.5)
 ER- and PR-11 (19.0)12 (18.5)
Number of metastatic lesions, n (%)
  ≤ 311 (19.0)14 (21.5)
  > 347 (81.0)51 (78.5)
Extent of disease
  < 3 sites36 (62.1)39 (60.0)
  ≥ 3 sites22 (37.9)26 (40.0)
Site of metastatic disease, n (%)
 Visceral disease46 (79.3)53 (81.5)
 Non-visceral disease12 (20.7)12 (18.5)
Median overall survival, months (95% CI)37.5 (25.4–49.6)35.1 (22.2–50.3)
Median progression-free survival, months (95% CI)11.3 (8.3–14.4)11.3 (9.7–16.0)
Response to treatment
 Complete response/partial response38 (71.7)40 (61.5)
 Stable disease13 (24.5)15 (23.1)
 Progressive disease2 (3.8)3 (4.6)